- Home
- SD vs CTNM Comparison
SD vs CTNM Comparison
Compare SD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SD | CTNM |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.9M | 416.1M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SD | CTNM |
|---|---|---|
| Price | $14.31 | $12.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 320.9K | 245.7K |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 40.92 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $155,930,000.00 | N/A |
| Revenue This Year | $31.95 | N/A |
| Revenue Next Year | $16.82 | N/A |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | ★ 29.68 | N/A |
| 52 Week Low | $8.81 | $3.35 |
| 52 Week High | $15.56 | $15.25 |
Technical Indicators
Market Signals| Indicator | SD | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 57.74 |
| Support Level | $14.23 | $11.66 |
| Resistance Level | $14.68 | $12.96 |
| Average True Range (ATR) | 0.34 | 0.73 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 32.60 | 56.56 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.